Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder

References

• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health. https://store.samhsa.gov/product/key-substance-use-and-mental-health-indicators-in-the-united-states-results-from-the-2019-national-survey-on-Drug-Use-and-Health/PEP20-07-01-001.
   Google Scholar
• Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Int Med. 2011 Feb 14;171:242–48. doi:10.1001/archinternmed.2010.511.
   PubMed Web of Science ®Google Scholar
• Hodder SL, Feinberg J, Strathdee SA, Shoptaw S, Altice FL, Ortenzio L, Beyrer C. The opioid crisis and HIV in the USA: deadly synergies. Lancet. 2021;397:1139–50. doi:10.1016/s0140-6736(21)00391-3.
   PubMed Web of Science ®Google Scholar
• Goodyear K, Haass-Koffler CL, Chavanne D. Opioid use and stigma: the role of gender, language and precipitating events. Drug Alcohol Depend. 2018 Apr 1;185:339–46. doi:10.1016/j.drugalcdep.2017.12.037.
   PubMed Web of Science ®Google Scholar
• Farris CA, Fenaughty AM. Social isolation and domestic violence among female drug users. Am J Drug Alcohol Abuse. 2002;28:339–51. doi:10.1081/ada-120002977.
   PubMed Web of Science ®Google Scholar
• Pettersen H, Landheim A, Skeie I, Biong S, Brodahl M, Oute J, Davidson L. How social relationships influence substance use disorder recovery: a collaborative narrative study. Subst Abuse. 2019;13:1178221819833379. doi:10.1177/1178221819833379.
   Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003 Sep 4;349:949–58. doi:10.1056/NEJMoa022164.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009 Nov 1;105:9–15. doi:10.1016/j.drugalcdep.2009.05.021.
   PubMed Web of Science ®Google Scholar
• Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984 Sep-Oct;12:577–81.
   PubMed Web of Science ®Google Scholar
• Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44:661–80. doi:10.2165/00003088-200544070-00001.
   PubMed Web of Science ®Google Scholar
• Petry NM, Bickel WK, Badger GJ. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Addiction. 2001 Jun;96:823–34. doi:10.1046/j.1360-0443.2001.9668234.x. PMID: 11399214.
   PubMed Web of Science ®Google Scholar
• Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacol (Berl). 1999 Sep;146:111–18. doi:10.1007/s002130051096. PMID: 10525745.
   PubMed Web of Science ®Google Scholar
• Pizzicato LN, Hom JK, Sun M, Johnson CC, Viner KM. Adherence to buprenorphine: an analysis of prescription drug monitoring program data. Drug Alcohol Depend. 2020 Nov 1;216:108317. doi:10.1016/j.drugalcdep.2020.108317.
   PubMed Web of Science ®Google Scholar
• Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018;9:59–78. doi:10.2147/SAR.S150253.
   PubMed Web of Science ®Google Scholar
• Kinsky S, Houck PR, Mayes K, Loveland D, Daley D, Schuster JM. A comparison of adherence, outcomes, and costs among opioid use disorder medicaid patients treated with buprenorphine and methadone: a view from the payer perspective. J Subst Abuse Treat. 2019 Sep;104:15–21. doi:10.1016/j.jsat.2019.05.015.
   PubMed Web of Science ®Google Scholar
• Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, Tsui JI. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract. 2019 Mar 13;14:11. doi:10.1186/s13722-019-0139-3.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Severt J, Cacciola J, Ruetsch C. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict. 2012 Jan-Feb;21:55–62. doi:10.1111/j.1521-0391.2011.00186.x.
   PubMed Web of Science ®Google Scholar
• Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014 Apr;46:456–62. doi:10.1016/j.jsat.2013.10.014.
   PubMed Web of Science ®Google Scholar
• Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the alcohol timeline followback when administered by telephone and by computer. Drug Alcohol Depend. 1996 Sep;42:49–54. doi:10.1016/0376-8716(96)01263-X.
   PubMed Web of Science ®Google Scholar
• Hjorthøj CR, Hjorthøj AR, Nordentoft M. Validity of timeline follow-back for self-reported use of cannabis and other illicit substances–systematic review and meta-analysis. Addict Behav. 2012 Mar;37:225–33. doi:10.1016/j.addbeh.2011.11.025.
   PubMed Web of Science ®Google Scholar
• Nordeck CD, Gryczynski J, O’Grady KE, Polak K, Svikis DS, McNeely J, Wu L-T, Schwartz RP. Comparison of timeline follow-back self-report and oral fluid testing to detect substance use in adult primary care patients. Drug Alcohol Depend. 2020 Apr 1;209:107939. doi:10.1016/j.drugalcdep.2020.107939.
   PubMed Web of Science ®Google Scholar
• Schramm ZA, Leroux BG, Radick AC, Ventura AS, Klein JW, Samet JH, Saxon AJ, Kim TW, Tsui JI. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial. Addict Sci Clin Pract. 2020 Jul 31;15:30. doi:10.1186/s13722-020-00203-9.
   PubMed Web of Science ®Google Scholar
• Tsui JI, Leroux BG, Radick AC, Schramm ZA, Blalock K, Labelle C, Heerema M, Klein JW, Merrill JO, Saxon AJ, et al. Video directly observed therapy for patients receiving office-based buprenorphine – a pilot randomized controlled trial. Drug Alcohol Depend. 2021 Oct 1;227:108917. doi:10.1016/j.drugalcdep.2021.108917.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA): practical tools for prescribing and promoting buprenorphine in primary care settings. Rockville (MD): National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration; 2021. SAMHSA Publication No. PEP21- 06-01-002.
   Google Scholar
• McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9:199–213. doi:10.1016/0740-5472(92)90062-S.
   PubMed Web of Science ®Google Scholar
• Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002 Dec 11;288:2880–83. doi:10.1001/jama.288.22.2880.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353:487–97. doi:10.1056/NEJMra050100.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O’Connor PG, Schottenfeld RS. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365–74. doi:10.1056/NEJMoa055255.
   PubMed Web of Science ®Google Scholar
• Stein M, Herman D, Conti M, Anderson B, Bailey G. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient ‘detoxification’: a randomized clinical trial. Addiction. 2020 Jan;115:82–94. doi:10.1111/add.14737.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, Arunogiri S, Hayes V, Hjelmström P, Svedberg A, et al. Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial. JAMA Netw Open. 2021 May 3;4:e219041. doi:10.1001/jamanetworkopen.2021.9041.
   PubMed Web of Science ®Google Scholar
• Hjorthoj CR, Hjorthoj AR, Nordentoft M. Validity of timeline follow-back for self-reported use of cannabis and other illicit substances–systematic review and meta-analysis. Addict Behav. 2012 Mar;37:225–33. doi:10.1016/j.addbeh.2011.11.025.
   PubMed Web of Science ®Google Scholar